GlyTherix Ltd has announced a significant step forward in targeted radiotherapy by signing a global clinical supply agreement with Eckert & Ziegler, a leader in isotopes for nuclear medicine. This collaboration will ensure the supply of GMP-grade Lutetium-177 chloride for GlyTherix’s clinical trials, which focus on treating aggressive cancers through the use of innovative antibody radiopharmaceuticals.
The approach developed by GlyTherix involves the use of Lu-177 combined with an antibody that targets Glypican-1, a protein found in several aggressive cancers. This method allows for localized radiation treatment, minimizing damage to healthy tissue. The clinical trials are scheduled to begin in Australia in early 2025, with U.S. trials following in 2026.
Dr. Brad Walsh, CEO of GlyTherix, highlighted the significance of this partnership in enhancing their global supply network, ensuring that high-quality isotopes are readily available for patients in need. Dr. Harald Hasselmann, CEO of Eckert & Ziegler, also expressed his enthusiasm for the collaboration, emphasizing the potential to support groundbreaking treatments in cancer therapy.
This partnership marks a pivotal moment in the development of targeted cancer treatments, promising a new era of therapy that could significantly improve patient outcomes.
